Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- ICH Completes Guidelines for Multiregional Clinical Trials; Could Accelerate Simultaneous Global Development
December 6, 2017
- MHLW Reviewing PMP in View of People’s Understanding: Health Insurance Chief
December 6, 2017
- Checklist Presented for Excluding Foundation-Funded Programs from “Specified Clinical Research”
December 6, 2017
- NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
December 5, 2017
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
- Opdivo Earns Orphan Status for Malignant Pleural Mesothelioma
December 4, 2017
- MHLW Floats Incentives to Stem Antibiotic Overuse, but Payer Reps Negative: Chuikyo
December 4, 2017
- MHLW Presents Example of COI Management Guidelines for “Specified Clinical Research”
December 4, 2017
- CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
- Keytruda Earns Lymphoma Nod, Novo’s Norditropin Label Expanded
December 1, 2017
- LDP Lawmakers Lash Out at Govt's Drug Pricing Proposals
December 1, 2017
- Full-Scale CEA Rollout to Be Delayed into FY2019: Official
December 1, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
- Abolish PMP or Narrow Down Its Scope: MOF Panel FY2018 Budget Recommendation
November 30, 2017
- Off-Year Revisions Should Be Confined to Limited Scope, JPWA Says at Chuikyo
November 30, 2017
- Regulators Will Be Involved in Safety Data Transition for LLP Withdrawals: MHLW Official
November 30, 2017
- MHLW to Announce Generic Usage Data by Insurers Twice Yearly Starting with FY2018 Data
November 30, 2017
- Exempt Some LLPs from New G1/G2 Price Scheme for Off-Patent Drugs: FPMAJ
November 30, 2017
- FPMAJ Chief Says Govt Proposal Is Fundamental Price Cut, Not Fundamental Reform: Chuikyo
November 30, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…